The global community acquired bacterial pneumonia (CABP) treatment market is expected to garner a market value of US$ 5 billion in 2023 and is expected to accumulate a market value of US$ 8.38 billion by registering a CAGR of 5.3% in the forecast period 2023 to 2033. The market for community acquired bacterial pneumonia (CABP) treatment registered a CAGR of 3.2% in the historical period 2018 to 2022.
The market for community acquired bacterial pneumonia (CABP) treatment is expected to experience steady growth in the coming years, driven by several factors. CABP is a type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
The global CABP treatment market includes a variety of drugs such as macrolides, fluoroquinolones, tetracyclines, and cephalosporins, which are used to treat bacterial infections. The market is expected to be driven by an increase in the incidence of CABP, an aging population, and the development of new and innovative drugs to treat the condition.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 5 Billion |
| Anticipated Forecast Value (2033) | US$ 8.38 Billion |
| Projected Growth Rate (2023 to 2033) | 5.3% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for community acquired bacterial pneumonia (CABP) treatment reflected a value of 3.2% during the historical period, 2018 to 2022. The incidence of CABP is increasing globally, driven by factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. This has led to an increase in demand for CABP treatment, driving the growth of the market.
Key players in the market are focused on developing new and innovative drugs to treat CABP, which is expected to drive the growth of the market. The availability of effective antibiotics is also expected to contribute to the growth of the market. Furthermore, Increasing healthcare spending in developing countries is expected to drive the growth of the market in these regions. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period, driven by the large population and increasing healthcare spending in countries such as India and China.
Overall, the market for community acquired bacterial pneumonia (CABP) treatment is expected to register a CAGR of 5.3% in the forecast period 2023 to 2033.
Increasing Prevalence of Community Acquired Bacterial Pneumonia (CABP) to push market growth
An increase in the incidence of Community Acquired Bacterial Pneumonia (CABP) is expected to drive the growth of the CABP treatment market. CABP is a common type of pneumonia that is acquired outside of a hospital or healthcare setting and is caused by bacteria such as Streptococcus pneumoniae, Haemophilus influenzae, and Legionella pneumophila.
The incidence of CABP is increasing globally due to factors such as smoking, chronic obstructive pulmonary disease (COPD), and an aging population. According to studies, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In addition to this, approximately 650 adults are hospitalized with CAP every year per 100,000 population in the United States, corresponding to 1.5 million unique CAP hospitalizations each year. As the incidence of CABP increases, the demand for CABP treatment is also expected to increase, which is likely to drive the growth of the market.
Moreover, the availability of effective antibiotics and the development of new and innovative drugs to treat CABP are also expected to contribute to the growth of the market.
In addition to these factors, increasing healthcare spending in developing countries and the presence of advanced healthcare infrastructure in developed regions are also expected to drive the growth of the CABP treatment market. Overall, the CABP treatment market is expected to experience steady growth in the coming years, driven by an increase in the incidence of CABP and other factors.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for community acquired bacterial pneumonia (CABP) can be high, particularly for advanced cases that require more invasive procedures. This can make it difficult for some patients to afford treatment, which can limit market growth.
Additionally, despite increasing awareness of Community Acquired Bacterial Pneumonia (CABP), there is still a lack of knowledge and understanding about the condition among the general population. This can lead to delays in diagnosis and treatment, which can impact the growth of the market.
Moreover, the regulatory requirements for approval of new treatments for Community Acquired Bacterial Pneumonia (CABP) can be stringent, which can limit the number of treatments that make it to market. This can impact the availability of new and innovative treatments for patients.
Increasing awareness and diagnosis of the condition Shaping Landscape for CABP Treatment in South & East Asia
The South and East Asia region is a growing market for community acquired bacterial pneumonia (CABP) treatment. The region includes countries such as India, China, Japan, South Korea, and the ASEAN countries. The market is driven by the increasing prevalence of CABP and the growing demand for effective treatments in the region.
This growth can be attributed to factors such as the increasing aging population, high burden of respiratory diseases, and increasing healthcare spending in countries such as India and China.
In India, the prevalence of CABP is high, especially among the elderly and immunocompromised populations. The market is witnessing the entry of new players, including local and international pharmaceutical companies, which is expected to increase competition and innovation in the market.
In China, the prevalence of CABP is also high, driven by factors such as air pollution, smoking, and an aging population. The government is taking steps to improve healthcare infrastructure and increase access to healthcare services, which is expected to drive the growth of the market.
Overall, the CABP treatment market in the South and East Asia region is turning out to be a promising market with significant growth potential. The increasing prevalence of CABP and the growing demand for effective treatments are expected to drive the growth of the market in the region in the coming years.
Increasing Focus on Technological Advancements Shaping Landscape for CABP Treatment in North America
The incidence of CABP is high in North America, particularly in the elderly and immunocompromised populations. This has led to a high demand for effective CABP treatments in the region. North America has a significant pipeline of new antibiotics under development for the treatment of CABP. This has led to the availability of new and effective treatments, which is expected to drive the growth of the market.
Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. This has helped to support the development and adoption of new treatments for Community Acquired Bacterial Pneumonia (CABP).
Overall, these factors are driving the growth of the Community Acquired Bacterial Pneumonia (CABP) Treatment market in North America. However, there are still challenges facing the market, including high treatment costs and the need for more effective and targeted therapies. Nonetheless, the market is expected to continue growing as new treatments and technologies are developed and as the awareness of community acquired bacterial pneumonia (CABP) continues to increase.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Intravenous (IV) route of administration to hold a significant share and push market growth
Among the different treatments for community acquired bacterial pneumonia (CABP), the intravenous (IV) route of administration is likely to account for a significant share of the market.
This is because IV antibiotics are often the first-line treatment for severe cases of CABP, where prompt and effective treatment is critical for improving patient outcomes. IV antibiotics can rapidly achieve therapeutic levels in the bloodstream, leading to a faster resolution of symptoms and a shorter hospital stay.
Additionally, IV antibiotics can be administered in a hospital or outpatient setting, depending on the severity of the illness, which adds to the convenience of treatment for patients.
Overall, while the IV route of administration is likely to account for a significant share of the CABP treatment market, the inhaled route of administration is an emerging segment that is expected to gain traction in the coming years.
Hospital pharmacies segment to hold a significant share and push market growth
Hospital pharmacies play a critical role in the management of CABP, as they are often the first point of contact for patients with CABP. Hospital pharmacies provide access to a wide range of medications and specialized treatment options, including invasive procedures and advanced imaging techniques, which are essential for the management of CABP.
In addition, hospital pharmacies have access to a multidisciplinary team of healthcare professionals, including physicians, nurses, and pharmacists, who can collaborate to provide comprehensive care to patients with CABP. This team-based approach is critical for the management of CABP, as it allows for individualized treatment plans that address the unique needs of each patient
Key players in the market include companies such as Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc., Combioxin SA, Takeda, TiGenix along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 5 billion |
| Market Value in 2033 | US$ 8.38 billion |
| Growth Rate | CAGR of 5.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
In 2023, the market may potentially be worth US$ 5 billion.
The market may steadily transform at a CAGR of 5.3% through 2033.
The market registered a HCAGR of 3.2 between 2018 and 2022.
The estimated value of the global market in 2033 is US$ 8.38 billion.
Hospital pharmacies are poised to capture a considerable market share.
1. Executive Summary | Community Acquired Bacterial Pneumonia (CABP) Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Pleuromutilin
5.3.2. Cephalosporin
5.3.3. Glycylcycline
5.3.4. Oxazolidinone
5.3.5. Ketolide
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Dose Form
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Dose Form, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Dose Form, 2023 to 2033
6.3.1. Solution
6.3.2. Tablet
6.4. Y-o-Y Growth Trend Analysis By Dose Form, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Dose Form, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
7.3.1. Oral
7.3.2. Intravenous
7.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Class
10.2.3. By Dose Form
10.2.4. By Route of Administration
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Dose Form
10.3.4. By Route of Administration
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Class
11.2.3. By Dose Form
11.2.4. By Route of Administration
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Dose Form
11.3.4. By Route of Administration
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Class
12.2.3. By Dose Form
12.2.4. By Route of Administration
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Dose Form
12.3.4. By Route of Administration
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Class
13.2.3. By Dose Form
13.2.4. By Route of Administration
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Dose Form
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Class
14.2.3. By Dose Form
14.2.4. By Route of Administration
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Dose Form
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Class
15.2.3. By Dose Form
15.2.4. By Route of Administration
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Dose Form
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Class
16.2.3. By Dose Form
16.2.4. By Route of Administration
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Class
16.3.3. By Dose Form
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Class
17.1.2.2. By Dose Form
17.1.2.3. By Route of Administration
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Class
17.2.2.2. By Dose Form
17.2.2.3. By Route of Administration
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Class
17.3.2.2. By Dose Form
17.3.2.3. By Route of Administration
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Class
17.4.2.2. By Dose Form
17.4.2.3. By Route of Administration
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Class
17.5.2.2. By Dose Form
17.5.2.3. By Route of Administration
17.5.2.4. By Distribution Channel
17.6. United kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Class
17.6.2.2. By Dose Form
17.6.2.3. By Route of Administration
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Class
17.7.2.2. By Dose Form
17.7.2.3. By Route of Administration
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Class
17.8.2.2. By Dose Form
17.8.2.3. By Route of Administration
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Class
17.9.2.2. By Dose Form
17.9.2.3. By Route of Administration
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Class
17.10.2.2. By Dose Form
17.10.2.3. By Route of Administration
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Class
17.11.2.2. By Dose Form
17.11.2.3. By Route of Administration
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Class
17.12.2.2. By Dose Form
17.12.2.3. By Route of Administration
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Class
17.13.2.2. By Dose Form
17.13.2.3. By Route of Administration
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Class
17.14.2.2. By Dose Form
17.14.2.3. By Route of Administration
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Class
17.15.2.2. By Dose Form
17.15.2.3. By Route of Administration
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Class
17.16.2.2. By Dose Form
17.16.2.3. By Route of Administration
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Class
17.17.2.2. By Dose Form
17.17.2.3. By Route of Administration
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Class
17.18.2.2. By Dose Form
17.18.2.3. By Route of Administration
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Class
17.19.2.2. By Dose Form
17.19.2.3. By Route of Administration
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Class
17.20.2.2. By Dose Form
17.20.2.3. By Route of Administration
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Class
17.21.2.2. By Dose Form
17.21.2.3. By Route of Administration
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Class
18.3.3. By Dose Form
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Nabriva Therapeutics
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Melinta Therapeutics
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Wakunaga Pharmaceutical Co. Ltd.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Actavis Generics
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Pfizer
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Paratek Pharmaceuticals
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Cumberland Pharmaceuticals Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Theravance Biopharma Inc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Merck Sharp & Dohme Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Cubist Pharmaceuticals LLC (Merck)
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Shionogi Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Allergan Plc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. Eagle Pharmaceutical Inc.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Combioxin
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Takeda
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
19.1.16. TiGenix
19.1.16.1. Overview
19.1.16.2. Product Portfolio
19.1.16.3. Profitability by Market Segments
19.1.16.4. Sales Footprint
19.1.16.5. Strategy Overview
19.1.16.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Community Acquired Bacterial Pneumonia (CABP) Treatment Market
